Artivion, Inc. (NYSE:AORT) Short Interest Update

Artivion, Inc. (NYSE:AORT - Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 3,220,000 shares, a growth of 7.3% from the October 31st total of 3,000,000 shares. Based on an average trading volume of 223,200 shares, the days-to-cover ratio is currently 14.4 days. Currently, 8.2% of the company's stock are short sold.

Analysts Set New Price Targets

AORT has been the topic of a number of recent research reports. Stifel Nicolaus raised their target price on Artivion from $28.00 to $30.00 and gave the stock a "buy" rating in a report on Friday, September 13th. JMP Securities assumed coverage on shares of Artivion in a report on Wednesday, October 23rd. They set an "outperform" rating and a $33.00 price objective on the stock. Needham & Company LLC reissued a "buy" rating and issued a $30.00 price objective on shares of Artivion in a report on Friday, September 27th. Finally, Oppenheimer lifted their price target on Artivion from $30.00 to $32.00 and gave the company an "outperform" rating in a research report on Friday, November 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Artivion has a consensus rating of "Buy" and an average price target of $31.00.

Artivion Price Performance

AORT traded up $0.06 on Tuesday, hitting $29.68. 197,996 shares of the company's stock were exchanged, compared to its average volume of 247,349. The firm has a 50-day moving average price of $27.17 and a 200-day moving average price of $25.91. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -1,484.00 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. Artivion has a fifty-two week low of $16.48 and a fifty-two week high of $30.00.

Insider Activity at Artivion

In other Artivion news, CAO Amy Horton sold 12,430 shares of the company's stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now owns 139,989 shares in the company, valued at approximately $3,664,912.02. This represents a 8.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.10% of the stock is currently owned by insiders.

Institutional Trading of Artivion

A number of hedge funds have recently bought and sold shares of AORT. The Manufacturers Life Insurance Company grew its holdings in shares of Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company's stock valued at $392,000 after purchasing an additional 481 shares in the last quarter. Louisiana State Employees Retirement System raised its position in Artivion by 3.1% during the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company's stock worth $510,000 after buying an additional 600 shares during the last quarter. Intech Investment Management LLC lifted its position in Artivion by 6.6% in the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company's stock valued at $280,000 after purchasing an additional 653 shares during the period. Quarry LP lifted its holdings in shares of Artivion by 210.8% in the 3rd quarter. Quarry LP now owns 1,209 shares of the company's stock valued at $32,000 after buying an additional 820 shares during the period. Finally, nVerses Capital LLC purchased a new stake in shares of Artivion during the 2nd quarter worth $28,000. Institutional investors and hedge funds own 86.37% of the company's stock.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.